Study to assess the efficacy and safety of Tab. Painmukti MJ, Painmukti cream and Painmukti-sandhical tablets in patients suffering from chronic pain

An open, randomized, placebo & comparator controlled, proof of concept comparative study to assess the efficacy and safety of Tab. Painmukti MJ, Painmukti cream and Painmukti-sandhical tablets in patients suffering from chronic pain (including arthritis)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/03/003508

Enrollment

Registered

2013-03-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1. Tab. Painmukti MJ 2. Painmukti-sandhical tablets 3. Painmukti cream: 1. Tab. Painmukti MJ 2 tablets twice a day for 3 months 2. Tab. Painmukti-sandhical 1 tablet twice a day for 3 mo

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from chronic pain due to different causes such as arthritis, frozen shoulder, tennis elbow, ankle sprain, low back pain, neurogenic pain (pain resulting from damage to the peripheral nerves or to the central nervous system itself), psychogenic pain (pain not due to past disease or injury or any visible sign of damage inside or outside the nervous system) 2.The duration of pain should be at least 3 months 3. Ready to abide by trial procedures and to give informed consent

Exclusion criteria

Exclusion criteria: 1. Patients showing signs and symptoms of complications such as bone and joint deformity. 2. Patients requiring long term treatment of oral and/or injectable steroids or surgical intervention. 3. Patients showing signs and symptoms of other systemic involvement. 4. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
1. At least 5% improvement in the pain score as compared to the group receiving the comparator therapy 2. At least 5% decrease in the requirement of analgesics/NSAIDs in patients receiving the test medications as compared to patients receiving comparator therapyTimepoint: 0 to 90 days	—

Secondary

Measure	Time frame
1. Less than 10% difference in the incidence of adverse events (including laboratory variables) between the 2 treatment groups. 2. 10% improvement in the Quality of Life score in patients receiving the test medications as compared to patients receiving comparator therapy Timepoint: 0 to 90 days	—

Countries

India

Contacts

Public ContactDr Renuka Munshi

TN Medical College and BYL Nair Hospital

renuka.munshi@gmail.com02223014713

Outcome results